New Canine Trial Links Enzyme Blend to Joint Mobility Gains

A newly published pilot trial on the enzyme blend Exclzyme Pet has added peer-reviewed data to a joint health supplement category. The study, conducted by Specialty Enzymes & Probiotics and published in Frontiers in Veterinary Science,¹ evaluated the ingredient's effect on canine osteoarthritis using a randomized, double-blind, placebo-controlled design.

"With joint issues affecting such a large percentage of companion animals, these findings are highly relevant for the pet supplement industry," said Reshma Rathi, vice president of Specialty Enzymes & Probiotics, in a statement announcing the results.²

What Did the Clinical Trial Measure?

Researchers enrolled 26 client-owned dogs diagnosed with arthritis, of whom 23 completed the 30-day protocol. Twelve dogs received Exclzyme Pet orally twice daily, while 11 received maltodextrin as a placebo.¹

Outcome measures included lameness, weight-bearing, joint mobility, pain scoring, and radiological assessment, along with serum C-reactive protein, a biomarker used in both human and veterinary medicine to track systemic inflammation.

The treatment group showed statistically significant reductions across multiple functional scores compared with placebo, and researchers reported a 56% reduction in C-reactive protein relative to the control group.

How Common Is Joint Disease in Dogs, and What Are the Current Treatment Options?

Osteoarthritis is widely regarded as one of the most frequently diagnosed joint conditions in canine veterinary medicine, though published prevalence estimates vary considerably depending on study population and diagnostic method.

Current management typically combines nonsteroidal anti-inflammatory drugs, weight control, physical therapy, and nutraceuticals such as glucosamine, chondroitin, and omega-3 fatty acids, none of which reverses joint degeneration outright. That gap between symptom management and structural repair is where enzyme-based and other novel ingredient categories are positioning themselves, though the clinical evidence base for most remains limited.

What Do the Findings Actually Show?

The trial's design is a meaningful step up from open-label or owner-reported studies common in the category, and the inclusion of an objective biomarker alongside functional scoring strengthens the case that the changes observed were not purely subjective.¹ At the same time, a 23-dog completion sample is small by clinical trial standards, even for a pilot study, and 30 days is a short window for assessing a chronic, progressive condition like osteoarthritis. The findings support further investigation rather than a definitive claim of disease-modifying benefit.

What Are the Study’s Limitations, and What Comes Next?

The trial was funded and conducted by the ingredient's manufacturer, which does not invalidate the results but warrants noting when interpreting outcomes. The authors themselves characterize the work as a pilot trial, and larger, independently replicated, longer-duration studies would be needed to confirm both the magnitude and durability of the reported effects.

For finished product manufacturers evaluating enzyme-based joint ingredients, the study represents a useful data point rather than a category-defining conclusion.

References

1. Wangikar PB, Deshpande AR, Arja A, Natu KV, Magdum RR. Efficacy and safety of supplementation of Exclzyme Pet for the management of arthritis and inflammatory symptoms in dogs: a randomized, double-blind, placebo-controlled pilot trial. Front Vet Sci. 2026. doi:10.3389/fvets.2026.1803915

2. Specialty Enzymes & Probiotics. Breakthrough study shows Exclzyme Pet supports joint health in 92% of dogs. PR Newswire. June 22, 2026. Accessed July 2, 2026. https://www.prnewswire.com/news-releases/breakthrough-study-shows-exclzyme-pet-supports-joint-health-in-92-of-dogs-302804761.html?tc=eml_cleartime&utm_source=ExclzymePetStudyRepsEmailJun26&utm_medium=ExclzymePetStudyRepsEmailJun26&utm_campaign=ExclzymePetStudyRepsEmailJun26&utm_id=ExclzymePetStudyRepsEmailJun26